Groupama Asset Managment Ascendis Pharma A/S Call Options Transaction History
Groupama Asset Managment
- $5.01 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding ASND
# of Institutions
258Shares Held
60.6MCall Options Held
130KPut Options Held
222K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.73 Billion22.55% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$936 Million4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.1MShares$871 Million10.24% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$748 Million0.32% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$727 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $9.53B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...